Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Copper-64 is a versatile radioactive isotope used in nuclear medicine for both diagnostic imaging and targeted radionuclide therapy. With a half-life of approximately 12.7 hours, it primarily decays via positron emission (17.8%), making it highly suitable for high-resolution Positron Emission Tomography (PET) imaging. It also undergoes beta-minus decay (38.4%) and electron capture (43.8%), which allows for potential therapeutic applications through the emission of Auger electrons and beta particles. In clinical practice, copper-64 is typically chelated to targeting ligands such as peptides (e.g., DOTATATE), monoclonal antibodies, or small molecules to visualize specific biological markers like somatostatin receptors or PSMA. It is frequently utilized as the diagnostic component of a "theranostic" pair, often matched with the therapeutic isotope copper-67.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on copper-64.